Aims: Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated front-line follicular lymphoma. We investigated sources of variability in G exposure and association of progression-free survival (PFS) with average concentration over induction (C meanIND ) in front-line follicular lymphoma patients treated with G plus chemotherapy (bendamustine, CHOP, or CVP) in the GALLIUM trial. Conclusions: It remains unclear whether for G-CHOP/CVP patients lower G exposure is a consequence of adverse disease biology and/or resistance to chemotherapy backbone (higher clearance in nonresponder patients, as demonstrated for rituximab)
rather than being the cause of poorer clinical outcome. A study with >1 dose level of G could help resolve this uncertainty.
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| INTRODUCTION
Targeting the CD20 antigen with monoclonal antibodies (mAbs) leads to depletion of B-cells in blood, bone marrow and other tissues. This therapeutic strategy has greatly improved the outcome of patients with B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukaemias (CLL) and is now considered standard of care for these diseases. [1] [2] [3] Rituximab, the first anti-CD20 mAb, is a chimeric, unmodified Type I anti-CD20 mAb of the IgG1 subclass. 4 New insights into the biology of CD20 and technical advances in antibody engineering led to the development of obinutuzumab (G, GA101, Gazyva or Gazyvaro; Hoffmann-La Roche), a humanized Type II anti-CD20 mAb glycoengineered to increase its affinity to Fc receptors on effector cells. Obinutuzumab was developed to have more potent direct cell killing activity and enhanced ability to activate effector cells and demonstrated its superiority over equal dosed rituximab in xenograft tumour models. 5 Based on three pivotal trials (CLL-11, GADOLIN, GALLIUM) obinutuzumab was approved for the front-line (1 L) treatment of patients with CLL, relapsed/refractory (R/R) and follicular lymphoma (FL). [6] [7] [8] While the approved rituximab dose is based on patient body surface area, trialists chose a fixed dose for obinutuzumab based on the insights that anti-CD20 mAbs have wide therapeutic windows and that fixed dosing may provide more convenience for physicians. 9, 10 The recommended dose and schedule of obinutuzumab was based on safety, efficacy, and pharmacokinetic (PK) data from two Phase 1b/2 studies 10 and confirmed in subsequent Phase 3 trials in CLL and NHL.
Obinutuzumab displays target-mediated drug disposition (TMDD),
i.e. the CD20 target antigen mediates the elimination of the drug.
Total obinutuzumab clearance is therefore the sum of two pathways:
a time-independent linear (through nonspecific endocytosis via Fcγ receptors [FCGR] ) and a time-dependent (through the target) pathway. [11] [12] [13] Early in treatment, the time-dependent clearance pathway makes a greater contribution to total clearance due to high levels of CD20+ cells (tumour burden), and diminishes thereafter as the CD20+ tumour volume reduces with repeated dosing. In contrast, the time-independent linear clearance of obinutuzumab remains constant throughout treatment. PK (i.e. mAb blood concentration) is thought to reflect CD20 occupancy and the dose and schedule of obinutuzumab was designed to ensure full target saturation throughout the entire dosing period. 10 Obinutuzumab exposure is mainly influenced by body weight, sex and tumour burden, 14 i.e. a male patient with high body weight and large tumour burden will have lower exposure than a female patient with low body weight and small tumour burden. However, if the chosen fixed dose is sufficient to ensure target saturation and hence ensure optimized efficacy in all patient subsets, such differences in exposure should not influence outcome. In patients where the disease progresses after obinutuzumab treatment, insufficient exposure to the drug may be considered as a possible contributor to the suboptimal response; however, there are also intrinsic disease and host factors that may affect patient outcome.
The GALLIUM study (NCT01332968) showed that obinutuzumabbased immunochemotherapy followed by obinutuzumab maintenance significantly improved progression-free survival (PFS) compared to rituximab-based immunochemotherapy followed by rituximab maintenance. 8 In this analysis, we studied the sources of variability in outcome amongst 1 L FL obinutuzumab-treated patients in the GALLIUM trial with particular emphasis on whether differences in obinutuzumab exposure affected outcome.
What is known about this subject
• Replacement of rituximab-with obinutuzumab-based immunochemotherapy and maintenance therapy in patients with front-line follicular lymphoma resulted in significantly longer progression-free survival in the GALLIUM trial.
• Drug exposure may correlate with outcome, but it is unclear whether lower exposure to monoclonal antibody causes inferior outcome or if it is a consequence of target consumption.
What this study adds
• Sources of variability in clinical outcome amongst obinutuzumab-treated patients were investigated.
• Variability in obinutuzumab exposure did not impact progression-free survival in obinutuzumabbendamustine-treated patients.
• In obinutuzumab-CHOP/CVP-treated patients, progression-free survival improved with increasing obinutuzumab exposure and was inferior in patients with high baseline tumour size and B symptoms.
| METHODS

| Study design
The GALLIUM trial is described in detail elsewhere. 8 Patients who attained a partial or complete response at the end of this induction phase then received maintenance therapy every 2 months for up to 2 years with the same antibody and dose they received during induction. Patients who had stable disease at the end of induction were followed on the same schedule but received no maintenance therapy ( Figure 1 ). The primary endpoint was investigator-assessed PFS in patients with FL. Characterization of PK in 1 L FL patients treated with obinutuzumab was an exploratory objective.
| PK analysis
PK samples for peak and trough (C trough ) obinutuzumab concentrations were collected as specified in Figure 1 . Serum obinutuzumab concentrations were analysed using a validated sandwich enzymelinked immunosorbent assay with a lower limit of quantitation of 4.05 ng/mL 14 and were included in a population PK (popPK) analysis using software NONMEM, Version 7. Overview of study design. Samples for assessment of peak concentrations were drawn 0-30 minutes after the end of infusion and trough samples were drawn 0-4 hours before the start of the next infusion. Pharmacokinetic samples were collected from the arm opposite to that receiving the infusion. In patients with indwelling catheters, a pharmacokinetic sample was drawn from the catheter after ample flushing was used as a metric of obinutuzumab exposure. In addition to C meanIND values, categories of C meanIND (low, medium, and high tertiles) were used as measures of exposure.
In addition, the influence on obinutuzumab exposure (C meanIND ) of several disease-related covariates (e.g. bone marrow involvement, serum level of β 2 -microglobulin, number of malignant cells [i.e. quantification of minimal residual disease {MRD} at baseline]) that were not tested in the popPK model was investigated univariately on GALLIUM data.
| Tumour burden assessment
Tumour burden, defined as the sum of product diameter of target lesions (SPD; as linear and log), was assessed by computed tomography (CT).
MRD was assessed by real-time, quantitative allele-specific oligonucleotide polymerase chain reaction (PCR), at baseline, midinduction, end of induction, and 6-monthly intervals to 24 months post end of induction/discontinuation. and at end of induction and where PET was available) or death from any cause, as described previously. 8 Response was assessed according to revised response criteria for malignant lymphoma with and without PET (at baseline, mid-induction and at end of induction and where PET was available). Response was assessed at mid-induction, end of induction, then assessed every 2 months for 2 years (maintenance phase), and then every 3-6 months, with CT performed every 6-12 months until progression or withdrawal from the study. PFS was defined as the time from randomization to the first occurrence of disease progression or relapse or death from any cause, as described previously.
| Genotyping
Genotyping of FCGR2A H131R, FCGR3A F158 V and FCGR2B I232T single nucleotide polymorphisms (SNPs) was performed in triplicate on genomic DNA samples alongside sequence-confirmed positive (Coriell Cell Repository, Camden, NJ, USA) and non-template controls as previously reported. 19 FCGR2A rs1801274 and FCGR3A rs396991
SNPs were genotyping using the commercially available TaqMan assays (Life Technologies, Paisley, UK), C_9077561_20 and C_25815666_10, respectively, according to the manufacturer's instructions. FCGR2B rs1050501 was genotyped using customdesigned primers and TaqMan probes. Each genotyping assay was prepared using the CAS-1200 PCR setup robot (Corbett Life Science, Qiagen) and amplification and allelic discrimination was performed using a Corbett Rotor-Gene 6000 (Corbett Life Science) and RotorGene Q series software 2.0.2 (Build 4), respectively. Genotyping results were confirmed by direct sequencing of PCR products. In cases of discrepancy between sequencing and TaqMan genotype data for FCGR2B, no valid result was recorded.
| Exposure-response analysis
Relationships between exposure, patient characteristics, or disease specific covariates and PFS were first explored graphically using Kaplan-Meier plots. To consider potential confounding factors, an exposure-response analysis of PFS was then performed in FL patients who received more than half of the planned induction doses of obinutuzumab (i.e. ≥5 CHOP/CVP, ≥4 bendamustine; n = 401) using semiparametric Cox proportional hazards (CPH) models. The relationships between obinutuzumab exposure with PFS was first characterized using the base CPH model. The hazard function in the CPH model is expressed as:
where λ 0 (t) is the baseline hazard function, X i is a vector of predictor variables, and β is a parameter vector estimated by maximum partial- 
| PK analysis
The GALLIUM data (n = 408) were added to the original popPK respectively, than for a patient with a tumour burden of 3000 mm 2 .
Initial time-dependent clearance is 48% higher in males, which further decreases the exposure in males during the first few weeks of treatment.
The initial total clearance that largely represents elimination through the CD20-target is 4.4-fold higher than the nonspecific time-independent clearance, which is similar to other IgG monoclonal antibodies. 22 The saturable (time-dependent) part of clearance decreased with time with a decay rate that is impacted by backbone chemotherapy.
In patients treated with G-Benda, the decay of the time dependent clearance occurred more rapidly with a half-life of 13. 
| DISCUSSION
Strategies to determine the optimal dosing of therapeutic antibodies have been refined over the past decades. For obinutuzumab, a novel type-II glycoengineered anti-CD20 mAb, two Phase 1b/2 studies were conducted to determine the optimal dose and schedule that would rapidly saturate the target and maintain this saturation. 10 PK characteristics have been thoroughly described for mAbs undergoing TMDD and are indicative of two clearance processes: (i) a concentration-and/or time-varying clearance which is associated with TMDD and which is saturable as the target is either fully occupied by the mAb or eliminated through the mechanism of action of FIGURE 4 Kaplan-Meier plots of progression-free survival in patients with high tumour burden (>5110 mm 2 ) at baseline by exposure category and chemotherapy backbone. Obinutuzumab-bendamustine patients (top left), obinutuzumab-CHOP (bottom left), obinutuzumab-CHOP/CVP (top right) and obinutuzumab-CVP patients (bottom right). Lower tertile: C meanIND = 68-313 μg/mL; middle tertile: C meanIND = 315-433 μg/mL; high tertile: C meanIND = 433-878 μg/mL the mAb; and (ii) a nonsaturable clearance process common to IgG-like mAbs where the mAb is cleared by nonspecific proteolytic action.
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For obinutuzumab, the time-varying clearance has been described previously in iNHL and CLL patients. 14 This initial obinutuzumab model was used to support the choice of an appropriate dosing regimen in CLL and iNHL patients. In order to achieve optimal clinical response, a high CD20 target saturation was desired throughout the dosing interval of obinutuzumab treatment.
In accordance with earlier results in patients with CLL or R/R FL, the exposure to obinutuzumab in 1 L treatment of patients with advanced FL in the GALLIUM trial apart from backbone chemotherapy was most strongly influenced by body weight, sex and tumour burden at baseline, but also serum albumin level and age. In prior studies, there was no evidence of any PK drug-drug interaction between obinutuzumab and backbone chemotherapies (Zelenetz et al., manuscript in preparation). supported the fact that bendamustine is often considered to be more effective than CHOP 24 and CHOP is considered to be more effective than CVP (without anthracycline). [25] [26] [27] 44 found that lower rituximab exposure in DLBCL patients was a consequence of high tumour burden leading to poorer prognosis (low rate of complete molecular response, PFS and overall survival) rather than a cause of inferior response. 44, 45 Likewise, exposure-response analyses of trastuzumab treatment in patients with HER2+ cancers have suggested that patients with low drug exposures had shorter overall survival times; however, increasing the dose did not lead to an improvement in efficacy. 28 Similar results have been found in CLL and DLBCL patients treated with dose dense treatment regimens of rituximab. [46] [47] [48] [49] Recently, a Food and Drug Administration pharmacometric reviewer highlighted the complexity of such analyses:
"When both the response and the drug target can affect the exposure, the causal relationship between the two becomes confounded.
Assessments of exposure-response relationships can then be biased even if baseline confounding factors are technically correctly adjusted." 50 In clinical practice, the parameters that could influence outcome
are not yet routinely measured making definitive conclusions difficult.
Total tumour burden is usually not directly assessable and only a small Defining exposure as the primary determinant of inferior clinical outcome should therefore be done with caution as other factors, such as intrinsic patient and disease characteristics could be relevant in PFS. In this analysis, we found that high tumour burden and presence of the FCG polymorphism 2b T232 T SNP increased the risk of disease progression or death. The FCGR2b 232 T-allele has been linked to reduced ability of the bound-mAb-CD20 complex to move to lipid rafts. 52 The FCGR2b acts as an inhibitory receptor for rituximab since its presence leads to internalization of the mAb/antigen complexes.
This process compromises mAb efficacy as it both consumes the mAb and downregulates the target so that cells become invisible to effector mechanisms. 41, 53, 54 In conclusion, exposure to obinutuzumab is influenced by several factors such as patient demographics, tumour burden and chemotherapy backbone (during the first few weeks of treatment) and is therefore variable among patients.
Nevertheless, this variability in exposure does not correlate with clinical outcome in patients treated with G-Benda. In those patients, intrinsic patient characteristics (male sex and tumour burden) are relevant contributors to the differences in PFS.
In patients treated with G-CHOP/CVP, the analysis suggests a correlation between lower exposure to obinutuzumab and poorer outcome. In those patients, higher obinutuzumab clearance (and therefore lower exposure) could be a consequence of poorer prognosis or resistance to chemotherapy backbone rather than the cause of poorer clinical outcome, as demonstrated for rituximab. 55 To resolve this uncertainty a randomized study with >1 dose level of obinutuzumab would be needed.
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